Heart intervention doesn't outweigh medicine in study

LEXINGTON, Ky. (March 27, 2007) -- In what some leading cardiologists are calling a "blockbuster" study, new research could alter the approach to treating patients who have cardiovascular disease but may not be at immediate risk of heart attack or stroke.

Co-authored by UK HealthCare's Linda and Jack Gill Heart Institute cardiologist Dr. David Booth, results of a five-year study released today showed that stable heart patients received no significant benefit in undergoing angioplasty when compared to patients treated with medication alone. The study, Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial, is published in the current issue of the New England Journal of Medicine and was presented this morning at the American College of Cardiologys annual scientific sessions in New Orleans.

More than 2,000 patients at 50 sites in North America, including the Lexington VA Medical Center at the University of Kentucky, were followed for four and a half years. The rate of death, heart attack and stroke was 19.5 percent in patients who had medication alone and 20 percent in patients who had percutaneous cardiac intervention, or PCI (procedures that involve clearing blocked vessels by inserting a catheter into a blood vessel, usually in the groin or arm, allowing the physician to access the blockage). While the study did show that patients who underwent PCI had the most relief from symptoms of angina, or mild chest pain that usually occurs with exertion and is relieved with rest and medication, patients who received medication alone also showed significant improvement in symptoms.

The study indicates that intervention can be safely deferred in stable heart patients, who in most cases may be treated initially with medication to lower cholesterol and prevent heart attack.

"The purpose of treating patients is to make them feel better, live longer, or both. For patients with stable, and I emphasize

Contact: Beth Goins
University of Kentucky

Page: 1 2

Related biology news :

1. Hearts of male and female rainbow trout are different
2. Heart failure: Intervention possibilities from imaging programmed cell loss
3. International Society for Heart and Lung Transplantation 27th Annual Meeting and Scientific Sessions
4. Heart rhythm genes possible factors in SIDS
5. Hearts or tails?
6. Heart smart: new drug improves blood flow
7. Heart has enough oxygen to survive hypothermia, CPR crucial
8. Defusing a time bomb: Heart attack risk-detection technology developed at UH
9. Heart failure wall stress drops 38% with moderate thyroid hormone therapy
10. New studies released at the Heart Rhythm Societys Annual Meeting
11. Molecular testing impact: Heart transplant patients benefit from new technology, easier monitoring

Post Your Comments:

(Date:6/28/2020)... (PRWEB) , ... June 25, 2020 , ... In an ... on innovations in accelerated Point of Care Testing solutions (POCT). Check local listings for ... are collected at medical offices and are shipped to labs throughout the country. Results ...
(Date:6/23/2020)... ... June 23, 2020 , ... Kemp ... announced that the company has received ISO9001:2015 certification for the development and ... industries. The decision to pursue ISO9001 accreditation demonstrates Kemp’s commitment to a ...
(Date:6/23/2020)... ... ... The field of quantitation of large molecules or proteins has been around ... the use of mass spectrometry in this field has gained a lot of momentum ... choose which approach to use (LBA or MS)?” In many cases, either technology ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... ... July 08, 2020 , ... Bode Technology, ... of laboratory operations through its COVID-19 testing service, Bode-CARES . Bode-CARES combines ... Bode-CARES provides a turnkey solution that includes a comprehensive collection and ...
(Date:7/10/2020)... ... 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology company ... Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. Dr. Nissenson will join ... Dr. Nissenson serves as an Emeritus Professor of Medicine at the David ...
(Date:7/1/2020)... ... 2020 , ... MedShift , a leading medical technology ... obstacles created as a result of COVID-19. As a provider at the forefront ... and medical manufacturers by expanding access to device offerings, technology services, and marketing ...
(Date:6/28/2020)... ... , ... The Indoor Lab, a leading provider of sensor solutions for monitoring ... to ensure cleanliness, distancing and occupancy with its patent pending WipeAway™ technology using Artificial ... provide a health performance index system that scores all aspects of compliance similar to ...
Breaking Biology Technology:
Cached News: